Lexeo Therapeutics (LXEO) Common Equity (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Common Equity data on file, last reported at $231.5 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 162.72% year-over-year to $231.5 million; the trailing twelve-month figure through Mar 2026 stood at $231.5 million (up 162.72% YoY), and the FY2025 full-year result was $246.7 million, up 111.11% from the prior year.
• Common Equity slipped to $231.5 million in Q1 2026, from $246.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $246.7 million in Q4 2025 to a low of -$162.8 million in Q3 2023.
• A 5-year average of $59.6 million and a median of $116.8 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 64.49% in 2023 and soared 239.46% in 2024, its largest moves.
• Tracing LXEO's Common Equity over 5 years: stood at -$113.0 million in 2022, then surged by 200.51% to $113.5 million in 2023, then advanced by 2.91% to $116.8 million in 2024, then soared by 111.11% to $246.7 million in 2025, then fell by 6.15% to $231.5 million in 2026.
• Business Quant data shows LXEO's Common Equity at $231.5 million in Q1 2026, $246.7 million in Q4 2025, and $120.8 million in Q3 2025.